Matches in SemOpenAlex for { <https://semopenalex.org/work/W2590987974> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2590987974 endingPage "e14646" @default.
- W2590987974 startingPage "e14646" @default.
- W2590987974 abstract "e14646 Background: Triweekly chemotherapy of paclitaxel and cisplatin has been proven to be effective in metastatic esophageal squamous cell carcinoma (ESCC).The purpose of this phase II trial was to evaluate efficiency and safety of biweekly chemotherapy of Paclitaxel and cisplatin in ESCC. Methods: Patients with advanced, surgically unresectable, or metastatic squamous cell carcinoma of the esophagus were enrolled; no prior chemotherapy for advanced or metastatic cancer; Karnofsky performance status (PS) ≥80; and adequate renal, hepatic, and hematologic function were treated with Paclitaxel 150mg/m2 iv d1 and cisplatin50- 60mg/m2 iv d2 every 2 weeks. Antitumor activity was assessed by computed tomography (CT) at baseline and after 8 weeks, and further by CT every 8 weeks. Results: 36 patients were recruited and 35 of them were evaluable for tumor response and safety. Patient characteristics were median age of 55 (42-71) years; gender, 78% male and 22% female. 3 patients had a complete response(8.5%); 16 had confirmed partial response and 2 had unconfirmed partial response. The overall response rate was 54.3%.9 had stable disease, giving a disease control rate (CR+PR+SD) of 85.7%.Median time to progression was 9.7 months (95% CI,8.2-11.1). Median survival time was 17.2 months (95% CI, 13,0-21.4). The most frequent grades 3–4 toxicity was neutropenia (60.0%; grade3 42.9%+grade4 17.1%). No toxic related death was observed. Conclusions: Biweekly chemotherapy of paclitaxel and cisplatin is a remarkably active and generally well-tolerated first-line treatment for patients with metastatic ESCC." @default.
- W2590987974 created "2017-03-03" @default.
- W2590987974 creator A5012791673 @default.
- W2590987974 creator A5028297003 @default.
- W2590987974 creator A5037865142 @default.
- W2590987974 creator A5042292928 @default.
- W2590987974 creator A5049224450 @default.
- W2590987974 creator A5075348524 @default.
- W2590987974 creator A5076386494 @default.
- W2590987974 creator A5079354616 @default.
- W2590987974 date "2011-05-20" @default.
- W2590987974 modified "2023-09-23" @default.
- W2590987974 title "Phase II trial of paclitaxel and cisplatin combination given biweekly as first-line chemotherapy in patients with advanced or metastatic squamous cell carcinoma of esophagus from a single center in China." @default.
- W2590987974 doi "https://doi.org/10.1200/jco.2011.29.15_suppl.e14646" @default.
- W2590987974 hasPublicationYear "2011" @default.
- W2590987974 type Work @default.
- W2590987974 sameAs 2590987974 @default.
- W2590987974 citedByCount "1" @default.
- W2590987974 countsByYear W25909879742022 @default.
- W2590987974 crossrefType "journal-article" @default.
- W2590987974 hasAuthorship W2590987974A5012791673 @default.
- W2590987974 hasAuthorship W2590987974A5028297003 @default.
- W2590987974 hasAuthorship W2590987974A5037865142 @default.
- W2590987974 hasAuthorship W2590987974A5042292928 @default.
- W2590987974 hasAuthorship W2590987974A5049224450 @default.
- W2590987974 hasAuthorship W2590987974A5075348524 @default.
- W2590987974 hasAuthorship W2590987974A5076386494 @default.
- W2590987974 hasAuthorship W2590987974A5079354616 @default.
- W2590987974 hasConcept C121608353 @default.
- W2590987974 hasConcept C126322002 @default.
- W2590987974 hasConcept C141071460 @default.
- W2590987974 hasConcept C143998085 @default.
- W2590987974 hasConcept C2776694085 @default.
- W2590987974 hasConcept C2776907518 @default.
- W2590987974 hasConcept C2777063308 @default.
- W2590987974 hasConcept C2777292972 @default.
- W2590987974 hasConcept C2777819096 @default.
- W2590987974 hasConcept C2778239845 @default.
- W2590987974 hasConcept C2778822529 @default.
- W2590987974 hasConcept C2778850193 @default.
- W2590987974 hasConcept C2779984678 @default.
- W2590987974 hasConcept C31760486 @default.
- W2590987974 hasConcept C71924100 @default.
- W2590987974 hasConcept C90924648 @default.
- W2590987974 hasConceptScore W2590987974C121608353 @default.
- W2590987974 hasConceptScore W2590987974C126322002 @default.
- W2590987974 hasConceptScore W2590987974C141071460 @default.
- W2590987974 hasConceptScore W2590987974C143998085 @default.
- W2590987974 hasConceptScore W2590987974C2776694085 @default.
- W2590987974 hasConceptScore W2590987974C2776907518 @default.
- W2590987974 hasConceptScore W2590987974C2777063308 @default.
- W2590987974 hasConceptScore W2590987974C2777292972 @default.
- W2590987974 hasConceptScore W2590987974C2777819096 @default.
- W2590987974 hasConceptScore W2590987974C2778239845 @default.
- W2590987974 hasConceptScore W2590987974C2778822529 @default.
- W2590987974 hasConceptScore W2590987974C2778850193 @default.
- W2590987974 hasConceptScore W2590987974C2779984678 @default.
- W2590987974 hasConceptScore W2590987974C31760486 @default.
- W2590987974 hasConceptScore W2590987974C71924100 @default.
- W2590987974 hasConceptScore W2590987974C90924648 @default.
- W2590987974 hasIssue "15_suppl" @default.
- W2590987974 hasLocation W25909879741 @default.
- W2590987974 hasOpenAccess W2590987974 @default.
- W2590987974 hasPrimaryLocation W25909879741 @default.
- W2590987974 hasRelatedWork W1918165413 @default.
- W2590987974 hasRelatedWork W1987606751 @default.
- W2590987974 hasRelatedWork W2100029565 @default.
- W2590987974 hasRelatedWork W2122995651 @default.
- W2590987974 hasRelatedWork W2183888492 @default.
- W2590987974 hasRelatedWork W2590598431 @default.
- W2590987974 hasRelatedWork W2590987974 @default.
- W2590987974 hasRelatedWork W94772370 @default.
- W2590987974 hasRelatedWork W2118693777 @default.
- W2590987974 hasRelatedWork W2561545475 @default.
- W2590987974 hasVolume "29" @default.
- W2590987974 isParatext "false" @default.
- W2590987974 isRetracted "false" @default.
- W2590987974 magId "2590987974" @default.
- W2590987974 workType "article" @default.